Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Ophthalmic Drugs: World Market Prospects 2012-2022
Management Report
Published: March 2012
Pages: 183
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 1699.00 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Indication Areas
What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions.
This study investigates prescription drugs treating human eye diseases. It lets you assess forecasted sales trends at world market, therapeutic submarket, product and national level to 2022.
How will 20 leading ophthalmic drugs - including Lucentis, Visudyne, Xalatan/Xalacom and Restasis - perform from 2012? Our investigation gives you business research and analysis with sales forecasts.
You also see forecasting of five submarkets to 2022, finding potential revenues:
• Glaucoma treatments
• Anti-allergy, anti-inflammatory and anti-infective agents
• Retinal disorder treatments
• Dry eye treatments
• Other medicines.
Find coverage of the R&D pipeline too, by therapeutic area, assessing trends and outlooks.
What will happen next? The pharma industry will improve treatment of ocular disorders and increase revenues there. The R&D pipeline in ophthalmology is strong. Also, improved drug delivery and new formulations will be important.
Visiongain predicts that the world market for ocular drugs will grow strongly from 2012 to 2022. It will be stimulated by increasing prevalence of eye disorders among aging populations. Some national treatment markets will grow fast; others will expand slowly.
What are leading companies doing? Our work discusses Allergan, Novartis, Pfizer, Roche and other pharmaceutical companies, evaluating prospects of the industry and market.
Sustained-release ocular implants, gene therapy and RNA interference technology will influence R&D, as will neuroprotective agents for glaucoma. Pipeline developments have strong potential. In 2012, under-met treatment needs remain.
What effects will competition have? New products - novel small molecules, generics and biologics - will change the sector. Many commercial opportunities for ophthalmic drugs exist, with high revenues possible to 2022. Our report shows and explains.
Revenue forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 120 tables and charts and six research interviews.
Eight ways Ophthalmic Drugs: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover revenue forecasts to 2022 for 20 leading products
• See market forecasting to 2022 for US, Japan, EU5, Brazil, China and India
• Assess leading companies, discovering activities and outlooks
• Review R&D, seeing pipeline trends by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, interviews with external authorities.
There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains.
Companies Listed
Acucela
Alcon (Novartis)
Alimera Sciences
Allergan
American Academy of Ophthalmology (AAO) [US]
American Society of Retina Specialists (ASRS) [US]
Apotex
Asahi Glass
Association for Research in Vision and Ophthalmology
AstraZeneca
Bausch & Lomb
Bayer
Biovitrum
Bristol-Myers Squibb
Can-Fite BioPharma
Cerimon Pharmaceuticals
Chugai Pharmaceutical Corp.
CombinatoRx
CoMentis
Daiichi Sankyo
Danube Pharmaceuticals
Eli Lilly
Esteve
European Medicines Agency (EMEA/EMA)
EyeGate Pharmaceuticals
Eyetech Pharmaceuticals
Food and Drug Administration (FDA) [US]
Fovea Pharmaceuticals
Galderma International SA (Nestlé and L'Oréal)
Genentech
GlaxoSmithKline
Gruenenthal
InSite Vision
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Johnson & Johnson
Kowa Company
Kyorin Pharmaceutical Co.
Kyowa Hakko Kirin Corp.
Laboratorios Sophia
LEO Pharma
Lux Biosciences
Meda Pharmaceuticals
Merck & Co.
Ministry of Health, Labour and Welfare [Japan]
Moorfields Eye Hospital [UK]
Mylan
National Eye Institute (NEI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
Neurotech
NicOx
NovaBay Pharmaceuticals
Novartis
Novex
Ophthotech
OPKO Health
OSI Pharmaceuticals
Othera Pharmaceuticals
Otsuka Pharmaceutical Corp.
Oxford Eye Hospital [UK]
OXiGENE
Paladin Labs
Pfizer
pSivida
QLT
Quark Pharmaceuticals
Ranbaxy Laboratories
Regeneron Pharmaceuticals
ReVision Therapeutics
Roche
Rutgers University, Springfield, New Jersey [US]
Santen Pharmaceutical Corp.
Sanwa Kagaku Kenkyusho Corp.
SARcode Corporation
Senju Pharmaceuticals
Shire Pharmaceuticals
Sirion Therapeutics
Sirna Therapeutics
SKS Ocular
Sunesis Pharmaceuticals
Symphony ViDA
Takeda Pharmaceuticals
Targeted Genetics
Teva Pharmaceutical Industries
ThromboGenics
University College of London (UCL), Institute of Ophthalmology [UK]
University of Aston, Birmingham [UK]
University of Oxford [UK]
Watson Pharmaceuticals